AXL and kidney disorder: Our previous and current data thus indicate that TYRO3 agonism may offer a new therapeutic avenue, based on these key findings: (a) TYRO3 expression negatively correlates with the progression of human glomerular disease, supporting a critical role of TYRO3 in kidney disease in humans (17); (b) single-cell transcriptomic data indicate that TYRO3 expression in the kidney is limited to podocytes, with relatively low expression in macrophages when compared with AXL and MER.